A Multicenter Real-world Clinical Study on the Efficacy and Safety of Ensartinib As Neoadjuvant Treatment for Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer (NSCLC) Patients.
Not yet recruitingOBSERVATIONAL
Enrollment
100
Participants
Timeline
Start Date
January 1, 2025
Primary Completion Date
December 31, 2027
Study Completion Date
June 30, 2028
Conditions
ALK PositiveEnsartinibNSCLCNeoadjuvant Therapy
All Listed Sponsors
lead
Harbin Medical University
OTHER
NCT06736561 - A Multicenter Real-world Clinical Study on the Efficacy and Safety of Ensartinib As Neoadjuvant Treatment for Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer (NSCLC) Patients. | Biotech Hunter | Biotech Hunter